Belite Bio's, Tinlarebant, targets eye diseases STGD1 and GA, showing promising results but with delayed phase 3 trial data.
Ocugen (OCGN) announced positive preliminary efficacy and safety data from the Phase 1 dose-escalation portion of the Phase 1/2 OCU410 ArMaDa ...
Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy
Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating ...
In both TEASE-1 and TEASE-3, gildeuretinol demonstrated a favorable safety and tolerability profile. There were no adverse ...
Clinical trials, TEASE-1 and TEASE-3, showed gildeuretinol significantly slowed retinal lesion growth and stabilized visual ...
Belite Bio, Inc. ( NASDAQ: BLTE) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Tom Lin - Chairman and Chief Executive Officer Hendrik Scholl - Chief Medical Officer Nathan Mata - Chief ...
Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX ...
We simultaneously track immune cell dynamics using label-free phase-contrast AOSLO at micron-level resolution. Retinal lesions were induced with 488 nm light focused onto photoreceptor (PR) outer ...
This article focuses on the pathogenesis of retinal detachment as well as the specific lesions and risk factors that lead to retinal detachment. Treatment options for both symptomatic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback